SCHEMBL1095137

SCHEMBL1095137

C[CH]OCCCCCCCC/C=C\CCCCCCCC

nearest known ligand 0.53

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LPAR2 Q9HBW0 3/20 0.52
LPAR3 Q9UBY5 3/20 0.52
LPAR1 Q92633 2/20 0.52
FAAH O00519 2/20 0.50
TRPV1 Q8NER1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16694791 0.94 ALDH1A1 (0.53) TRPV1
SCHEMBL16694326 0.94 ALDH1A1 (0.53) TRPV1
SCHEMBL983617 0.89 THRB (0.44) LPAR2LPAR3LPAR1
SCHEMBL17416222 0.89 THRB (0.44) LPAR2LPAR3LPAR1
SCHEMBL335169 0.89 THRB (0.44) LPAR2LPAR3LPAR1
SCHEMBL63139 0.89
SCHEMBL262090 0.89 THRB (0.44) LPAR2LPAR3LPAR1
SCHEMBL653851 0.89 THRB (0.44) LPAR2LPAR3LPAR1
SCHEMBL981959 0.89 THRB (0.44) LPAR2LPAR3LPAR1
SCHEMBL134759 0.89 THRB (0.44) LPAR2LPAR3LPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443130-B1 PHOSPHONATES SYNTHONS FOR THE SYNTHESIS OF PHOSPHONATES DERIVATIVES SHOWING BETTER BIOAVAILABILITY CENTRE NAT RECH SCIENT (FR) 2016-08-03 EP claimed
WO-2023214017-A1 CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER VIROVET NV (BE) 2023-11-09 WO disclosed
EP-2871178-B1 CATIONIC LIPID KYOWA KIRIN CO LTD (JP) 2020-12-23 EP disclosed
US-20200368173-A1 NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE KYOWA KIRIN CO., LTD. (JP) 2020-11-26 US disclosed
EP-3662913-A1 NUCLEIC-ACID-CONTAINING LIPID NANOPARTICLES Kyowa Kirin Co., Ltd. (JP) 2020-06-10 EP disclosed
US-10342758-B2 Cationic lipid KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 US disclosed
US-20180353434-A1 NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES KYOWA HAKKO KIRIN CO., LTD. (JP) 2018-12-13 US disclosed
EP-3275448-A1 NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES Kyowa Hakko Kirin Co., Ltd. (JP) 2018-01-31 EP disclosed
US-20150174261-A1 CATIONIC LIPID KYOWA KIRIN CO., LTD. (JP) 2015-06-25 US disclosed
EP-2871178-A1 CATIONIC LIPID Kyowa Hakko Kirin Co., Ltd. (JP) 2015-05-13 EP disclosed
US-20090156545-A1 Substituted Phosphate Esters of Nucleoside Phosphonates THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2009-06-18 US disclosed
US-20090005346-A1 Azacytosine Derivatives Useful as Antiviral Agents K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) 2009-01-01 US disclosed
WO-2008131501-A2 NEW ANTI-VIRAL NUCLEOSIDE ANALOGS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2008-11-06 WO disclosed
WO-2008131502-A2 ANTIVIRAL COMPOUNDS OF THE ADAMANTANE TYPE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2008-11-06 WO disclosed
EP-1966226-A2 AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS K.U.Leuven Research & Development (BE) 2008-09-10 EP disclosed
EP-1866319-A1 PHOSPHONO-PENT-2-EN-1-YL NUCLEOSIDES AND ANALOGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-12-19 EP disclosed
WO-2007065231-A2 AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2007-06-14 WO disclosed
WO-2006137953-A1 PHOSPHONO-PENT-2-EN-1-YL NUCLEOSIDES AND ANALOGS THE REGENTS OF THE UNIVERISITY OF CALIFORNIA (US) 2006-12-28 WO disclosed
WO-2006130217-A2 SUBSTITUTED PHOSPHATE ESTERS OF NUCLEOSIDE PHOSPHONATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-12-07 WO disclosed
WO-2006076015-A2 1-[2-(PHOSPHONOMETHOXY)ETHYL]-CYTOSINE AND ANALOGS THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156545-A1 Substituted Phosphate Esters of Nucleoside Phosphonates PNP, TYMP, ENPP1 LPAR2 2121/4885LPAR3 2076/4885LPAR1 1954/4885
US-20090005346-A1 Azacytosine Derivatives Useful as Antiviral Agents ITPA, ZC3HAV1, MTAP LPAR2 3510/4885LPAR3 2824/4885LPAR1 2908/4885
US-20180353434-A1 NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES FASN, ABHD16A, PHAX LPAR2 300/4885LPAR3 260/4885LPAR1 213/4885
US-10342758-B2 Cationic lipid LIPA, LCLAT1, RNASEH1 LPAR2 14/4885LPAR3 9/4885LPAR1 10/4885
US-20150174261-A1 CATIONIC LIPID LIPA, LCLAT1, RNASEH1 LPAR2 14/4885LPAR3 9/4885LPAR1 10/4885
US-20200368173-A1 NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE LIPA, LIPC, PNLIP LPAR2 131/4885LPAR3 85/4885LPAR1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.